SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001664710-24-000026
Filing Date
2024-03-05
Accepted
2024-03-05 08:01:00
Documents
14
Period of Report
2024-02-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K kros-20240229.htm   iXBRL 8-K 31936
  Complete submission text file 0001664710-24-000026.txt   160169

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20240229.xsd EX-101.SCH 1901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20240229_lab.xml EX-101.LAB 24851
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20240229_pre.xml EX-101.PRE 13046
15 EXTRACTED XBRL INSTANCE DOCUMENT kros-20240229_htm.xml XML 2823
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 24718328
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)